Kouretas D, Kountouras J, Tsapas G, Anastasiades N, Tsakiri I, Antonoglou O
Research Department, Theagenion Cancer Hospital, Thessaloniki, Greece.
Anticancer Res. 1990 Jul-Aug;10(4):1025-8.
The serum protective activity against acid precipitation of poly (U) and a-fetoprotein levels were compared in 39 cirrhotic patients with hepatocellular carcinoma (HCC) and in 33 patients with chronic liver disease (CLD) alone, in order to differentiate malignant and nonmalignant chronic liver disease. All but one (97.4%) patients with HCC were found to have serum protective activity levels of greater than or equal to 21 micrograms/ml, whereas all but one (97%) patients with CLD had serum protective activity levels of less than or equal to 20 micrograms/ml. Mean serum protective activity levels were significantly higher in the HCC group than in those with CLD (p less than 0.0001). Serum a-fetoprotein concentrations of over 500 ng/ml, suggesting malignancy, were observed in 54% of patients with HCC and in 15% of patients with CLD. Application of the best discriminating values for protective activity (greater than 21 micrograms/ml) and for a-fetoprotein (greater than 500 ng/ml) to 72 patients with or without HCC revealed an efficiency of 97.2% for protective activity and only 68.1% for a-fetoprotein.
为鉴别恶性和非恶性慢性肝病，对39例肝硬化合并肝细胞癌（HCC）患者和33例单纯慢性肝病（CLD）患者的血清针对酸性沉淀的保护活性及甲胎蛋白水平进行了比较。除1例（97.4%）HCC患者外，其余患者血清保护活性水平均大于或等于21微克/毫升；而除1例（97%）CLD患者外，其余患者血清保护活性水平均小于或等于20微克/毫升。HCC组的平均血清保护活性水平显著高于CLD组（p<0.0001）。54%的HCC患者和15%的CLD患者血清甲胎蛋白浓度超过500纳克/毫升，提示存在恶性病变。将保护活性（大于21微克/毫升）和甲胎蛋白（大于500纳克/毫升）的最佳鉴别值应用于72例有或无HCC的患者，结果显示保护活性的鉴别效率为97.2%，而甲胎蛋白的鉴别效率仅为68.1%。
